IN2014MN01568A - - Google Patents

Info

Publication number
IN2014MN01568A
IN2014MN01568A IN1568MUN2014A IN2014MN01568A IN 2014MN01568 A IN2014MN01568 A IN 2014MN01568A IN 1568MUN2014 A IN1568MUN2014 A IN 1568MUN2014A IN 2014MN01568 A IN2014MN01568 A IN 2014MN01568A
Authority
IN
India
Prior art keywords
dose
rasagiline
pramipexole
subtherapeutic
fixed
Prior art date
Application number
Other languages
English (en)
Inventor
Nurit Livnah
Pninit Litman
Sarit Zaksh
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48781101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01568(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of IN2014MN01568A publication Critical patent/IN2014MN01568A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1568MUN2014 2012-01-12 2013-01-10 IN2014MN01568A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585824P 2012-01-12 2012-01-12
PCT/IL2013/050025 WO2013105092A1 (en) 2012-01-12 2013-01-10 Fixed dose combination therapy of parkinson's disease

Publications (1)

Publication Number Publication Date
IN2014MN01568A true IN2014MN01568A (de) 2015-05-08

Family

ID=48781101

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1568MUN2014 IN2014MN01568A (de) 2012-01-12 2013-01-10

Country Status (22)

Country Link
US (1) US20150079187A1 (de)
EP (1) EP2802319B1 (de)
JP (1) JP6243351B2 (de)
KR (2) KR102276896B1 (de)
CN (1) CN104168896B (de)
AU (1) AU2013208653B2 (de)
CA (1) CA2860952C (de)
CY (1) CY1119793T1 (de)
DK (1) DK2802319T3 (de)
ES (1) ES2655676T3 (de)
HK (1) HK1203847A1 (de)
HU (1) HUE038029T2 (de)
IL (1) IL233572B (de)
IN (1) IN2014MN01568A (de)
LT (1) LT2802319T (de)
MX (1) MX360409B (de)
NO (2) NO2802319T3 (de)
PL (1) PL2802319T3 (de)
PT (1) PT2802319T (de)
RS (1) RS56742B1 (de)
RU (1) RU2642962C9 (de)
WO (1) WO2013105092A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104367565A (zh) * 2014-11-21 2015-02-25 哈尔滨圣吉药业股份有限公司 一种盐酸普拉克索缓释微丸
CN105147627B (zh) * 2015-08-19 2019-04-12 天津红日药业股份有限公司 一种含有盐酸普拉克索的药物组合物及其制备方法
US11234961B2 (en) * 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
KR20210106477A (ko) * 2018-12-19 2021-08-30 갈렉토 바이오테크 에이비 5-브로모피리딘-3-일 3-데옥시-3-[4-(3,4,5-트리플루오로페닐)-1h-1,2,3-트리아졸-1-일]-1-티오-알파-d-갈락토피라노사이드의 비정질 형태
EP4070793A4 (de) * 2019-12-06 2023-06-14 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmazeutische zusammensetzung, ergänzungssatz und anwendung davon
WO2023112024A1 (en) * 2021-12-14 2023-06-22 Pharma Two B Ltd. Method of treating parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163725A0 (en) * 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
AU2005215136A1 (en) * 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CN101442997B (zh) * 2006-04-03 2012-11-14 泰华制药工业有限公司 雷沙吉兰用于治疗多动腿综合征
EP2150239A1 (de) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Kombination mit einer pramipexol oder ein pharmazeutisch annehmbares salz davon enthaltenden tablettenformulierung mit verlängerter freisetzung
NZ590291A (en) * 2008-06-06 2013-11-29 Pharma Two B Ltd Pharmaceutical compositions for treatment of parkinson's disease
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof

Also Published As

Publication number Publication date
HUE038029T2 (hu) 2018-09-28
CN104168896B (zh) 2018-08-10
NO2901008T3 (de) 2018-08-04
EP2802319A1 (de) 2014-11-19
RS56742B1 (sr) 2018-03-30
AU2013208653B2 (en) 2017-04-20
IL233572A0 (en) 2014-08-31
IL233572B (en) 2020-05-31
HK1203847A1 (en) 2015-11-06
PL2802319T3 (pl) 2018-04-30
KR20140138629A (ko) 2014-12-04
CA2860952C (en) 2020-09-15
EP2802319A4 (de) 2015-07-01
RU2014132940A (ru) 2016-02-27
NO2802319T3 (de) 2018-03-24
CN104168896A (zh) 2014-11-26
RU2017146994A3 (de) 2021-03-16
US20150079187A1 (en) 2015-03-19
JP2015508411A (ja) 2015-03-19
RU2642962C9 (ru) 2018-05-04
RU2642962C2 (ru) 2018-01-29
EP2802319B1 (de) 2017-10-25
RU2017146994A (ru) 2018-10-22
AU2013208653A1 (en) 2014-08-28
LT2802319T (lt) 2018-04-10
MX360409B (es) 2018-10-30
ES2655676T3 (es) 2018-02-21
CY1119793T1 (el) 2018-06-27
JP6243351B2 (ja) 2017-12-06
PT2802319T (pt) 2018-01-29
RU2771522C2 (ru) 2022-05-05
DK2802319T3 (da) 2018-01-29
WO2013105092A1 (en) 2013-07-18
KR20200013791A (ko) 2020-02-07
MX2014008537A (es) 2014-11-25
KR102276896B1 (ko) 2021-07-14
CA2860952A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
IL253225B (en) Sulfamoyl-arylamides and their use as drugs to treat jaundice b
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
IN2012DN06720A (de)
NZ702663A (en) Nuclear transport modulators and uses thereof
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IN2014MN01568A (de)
GB201111485D0 (en) Drug composition and its use in therapy
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
IL260078B (en) Therapy used to treat Gaucher disease
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
GB201115977D0 (en) Neurodevelopmental disorders
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
UA77604U (ru) Производное 1,2,4-триазола, проявляющее актопротекторную активность
NZ623275A (en) Treatment of ocular disease
UA53217U (en) Mask for therapy and general health improvement
UA94528C2 (ru) Применение производных глюкозамина в качестве церебропротекторных сРедств
PL397528A1 (pl) Gorset dynamiczno-stymulujacy do leczenia choroby Schumanna